 Mark Abzug
Concepts (408)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enterovirus Infections | 21 | 2019 | 160 | 3.030 |
Why?
| | HIV Infections | 27 | 2022 | 2469 | 2.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 9 | 2017 | 257 | 1.810 |
Why?
| | Pneumococcal Vaccines | 5 | 2021 | 132 | 1.750 |
Why?
| | Antiviral Agents | 11 | 2021 | 648 | 1.560 |
Why?
| | Pregnancy Complications, Infectious | 14 | 2015 | 289 | 1.540 |
Why?
| | Enterovirus | 9 | 2019 | 72 | 1.280 |
Why?
| | Hematopoietic Stem Cell Transplantation | 4 | 2021 | 522 | 1.090 |
Why?
| | Immunologic Memory | 3 | 2013 | 312 | 1.030 |
Why?
| | Pneumococcal Infections | 3 | 2013 | 91 | 0.990 |
Why?
| | Immunization, Secondary | 4 | 2021 | 82 | 0.970 |
Why?
| | Oxadiazoles | 4 | 2015 | 32 | 0.900 |
Why?
| | Paralysis | 4 | 2018 | 67 | 0.780 |
Why?
| | Child | 54 | 2023 | 18557 | 0.730 |
Why?
| | Sinusitis | 7 | 2013 | 175 | 0.650 |
Why?
| | Triazoles | 2 | 2018 | 131 | 0.630 |
Why?
| | Vaccination | 4 | 2017 | 1205 | 0.630 |
Why?
| | Anti-Retroviral Agents | 8 | 2022 | 207 | 0.620 |
Why?
| | Mucositis | 1 | 2018 | 18 | 0.620 |
Why?
| | Meningoencephalitis | 1 | 2017 | 24 | 0.600 |
Why?
| | Influenza, Human | 5 | 2015 | 549 | 0.590 |
Why?
| | Antibodies, Bacterial | 4 | 2013 | 119 | 0.590 |
Why?
| | Myelitis | 4 | 2019 | 88 | 0.580 |
Why?
| | Theilovirus | 4 | 2000 | 5 | 0.560 |
Why?
| | Encephalitis | 1 | 2017 | 128 | 0.530 |
Why?
| | Graft vs Host Disease | 1 | 2018 | 210 | 0.530 |
Why?
| | Influenza A Virus, H1N1 Subtype | 3 | 2015 | 139 | 0.530 |
Why?
| | Neonatal Sepsis | 1 | 2015 | 4 | 0.510 |
Why?
| | Encephalomyelitis, Acute Disseminated | 1 | 2015 | 13 | 0.510 |
Why?
| | Central Nervous System Viral Diseases | 4 | 2019 | 63 | 0.510 |
Why?
| | Immunocompromised Host | 5 | 2021 | 197 | 0.500 |
Why?
| | Herpes Simplex | 4 | 2017 | 88 | 0.500 |
Why?
| | Disease Outbreaks | 6 | 2019 | 310 | 0.490 |
Why?
| | Influenza Vaccines | 3 | 2015 | 498 | 0.490 |
Why?
| | Placenta | 6 | 2000 | 623 | 0.460 |
Why?
| | Neuromyelitis Optica | 1 | 2015 | 114 | 0.460 |
Why?
| | Humans | 87 | 2023 | 115902 | 0.450 |
Why?
| | Infant, Newborn | 25 | 2018 | 5090 | 0.450 |
Why?
| | Child, Preschool | 27 | 2022 | 9177 | 0.450 |
Why?
| | CD4 Lymphocyte Count | 8 | 2022 | 257 | 0.450 |
Why?
| | Neuromuscular Diseases | 3 | 2019 | 90 | 0.440 |
Why?
| | Adolescent | 35 | 2022 | 17956 | 0.440 |
Why?
| | Infant | 26 | 2020 | 8002 | 0.430 |
Why?
| | Drug Discovery | 1 | 2013 | 124 | 0.420 |
Why?
| | Measles Vaccine | 1 | 2012 | 17 | 0.420 |
Why?
| | Mucormycosis | 3 | 2005 | 20 | 0.410 |
Why?
| | Female | 61 | 2022 | 60081 | 0.410 |
Why?
| | Male | 52 | 2022 | 56127 | 0.400 |
Why?
| | RNA, Viral | 12 | 2013 | 561 | 0.400 |
Why?
| | Anti-HIV Agents | 5 | 2022 | 669 | 0.380 |
Why?
| | Meningococcal Vaccines | 2 | 2012 | 49 | 0.370 |
Why?
| | Cardiovirus Infections | 2 | 2000 | 3 | 0.370 |
Why?
| | Viral Vaccines | 2 | 2009 | 80 | 0.360 |
Why?
| | Candidemia | 2 | 2023 | 6 | 0.360 |
Why?
| | Oxazoles | 4 | 2015 | 29 | 0.350 |
Why?
| | Viral Load | 7 | 2017 | 406 | 0.350 |
Why?
| | Candidiasis, Invasive | 2 | 2023 | 5 | 0.340 |
Why?
| | Hepatitis B Vaccines | 1 | 2009 | 46 | 0.340 |
Why?
| | AIDS-Related Opportunistic Infections | 3 | 2015 | 117 | 0.330 |
Why?
| | Bacterial Vaccines | 1 | 2009 | 60 | 0.320 |
Why?
| | Fatigue Syndrome, Chronic | 1 | 2008 | 16 | 0.310 |
Why?
| | Pertussis Vaccine | 1 | 2007 | 21 | 0.300 |
Why?
| | Communicable Diseases, Emerging | 1 | 2008 | 28 | 0.300 |
Why?
| | Poliomyelitis | 2 | 1997 | 27 | 0.300 |
Why?
| | Mycetoma | 2 | 2004 | 6 | 0.290 |
Why?
| | Viremia | 5 | 2021 | 120 | 0.280 |
Why?
| | Rhinitis | 3 | 2009 | 128 | 0.280 |
Why?
| | Fetus | 3 | 2000 | 703 | 0.280 |
Why?
| | Immunoglobulins, Intravenous | 3 | 1997 | 123 | 0.280 |
Why?
| | Pregnancy | 16 | 2021 | 5555 | 0.260 |
Why?
| | Antibodies, Viral | 5 | 2022 | 520 | 0.260 |
Why?
| | Anti-Bacterial Agents | 3 | 2013 | 1486 | 0.250 |
Why?
| | Antifungal Agents | 4 | 2023 | 134 | 0.250 |
Why?
| | Enterovirus B, Human | 3 | 2001 | 24 | 0.240 |
Why?
| | Meningitis, Viral | 2 | 2004 | 21 | 0.240 |
Why?
| | Maxillary Sinusitis | 2 | 2004 | 7 | 0.230 |
Why?
| | Maus Elberfeld virus | 3 | 1993 | 5 | 0.230 |
Why?
| | Global Health | 2 | 2018 | 292 | 0.230 |
Why?
| | Cytomegalovirus | 2 | 2016 | 144 | 0.220 |
Why?
| | Interferon-gamma | 2 | 2015 | 731 | 0.210 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 2017 | 221 | 0.210 |
Why?
| | Placenta Diseases | 2 | 1995 | 13 | 0.210 |
Why?
| | Fetal Diseases | 3 | 2000 | 148 | 0.200 |
Why?
| | Centralized Hospital Services | 1 | 2001 | 6 | 0.200 |
Why?
| | Pneumonia, Viral | 2 | 2021 | 343 | 0.200 |
Why?
| | Oseltamivir | 2 | 2012 | 11 | 0.200 |
Why?
| | United States | 13 | 2021 | 12340 | 0.200 |
Why?
| | Hepatitis, Viral, Human | 1 | 2001 | 25 | 0.200 |
Why?
| | Retrospective Studies | 14 | 2022 | 12616 | 0.190 |
Why?
| | Colorado | 7 | 2021 | 4122 | 0.190 |
Why?
| | Research Support as Topic | 1 | 2001 | 108 | 0.190 |
Why?
| | Streptococcus pneumoniae | 3 | 2014 | 133 | 0.180 |
Why?
| | Young Adult | 14 | 2017 | 10517 | 0.180 |
Why?
| | Ethmoid Sinusitis | 1 | 1999 | 1 | 0.180 |
Why?
| | Hydrops Fetalis | 1 | 1999 | 13 | 0.170 |
Why?
| | Intracranial Hemorrhages | 1 | 2000 | 76 | 0.170 |
Why?
| | Uterine Diseases | 1 | 1999 | 14 | 0.170 |
Why?
| | Neurodevelopmental Disorders | 1 | 2021 | 109 | 0.170 |
Why?
| | Polymerase Chain Reaction | 4 | 2016 | 1001 | 0.170 |
Why?
| | Embryonic Development | 1 | 2000 | 115 | 0.170 |
Why?
| | Follow-Up Studies | 8 | 2022 | 4446 | 0.170 |
Why?
| | Drug Resistance, Microbial | 1 | 1999 | 66 | 0.170 |
Why?
| | Blood Coagulation Disorders | 1 | 2001 | 196 | 0.160 |
Why?
| | Mastoiditis | 2 | 2014 | 5 | 0.160 |
Why?
| | Nervous System Diseases | 2 | 2019 | 253 | 0.160 |
Why?
| | Fluoxetine | 1 | 2018 | 46 | 0.160 |
Why?
| | Enterovirus D, Human | 2 | 2018 | 72 | 0.160 |
Why?
| | Double-Blind Method | 3 | 2015 | 1665 | 0.160 |
Why?
| | Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2009 | 11 | 0.160 |
Why?
| | Antibodies, Monoclonal | 2 | 2022 | 1262 | 0.150 |
Why?
| | Hospitals, Pediatric | 1 | 2001 | 478 | 0.150 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 794 | 0.150 |
Why?
| | HIV-1 | 2 | 2015 | 769 | 0.150 |
Why?
| | Arboviruses | 1 | 2017 | 10 | 0.150 |
Why?
| | Biliary Atresia | 1 | 2020 | 185 | 0.150 |
Why?
| | Treatment Outcome | 9 | 2020 | 9165 | 0.150 |
Why?
| | Nucleic Acid Hybridization | 6 | 1991 | 187 | 0.150 |
Why?
| | In Situ Hybridization | 4 | 2000 | 298 | 0.150 |
Why?
| | Administration, Intravenous | 1 | 2018 | 126 | 0.150 |
Why?
| | Disease Transmission, Infectious | 1 | 2018 | 57 | 0.150 |
Why?
| | Allografts | 1 | 2018 | 127 | 0.150 |
Why?
| | Acyclovir | 2 | 2015 | 100 | 0.150 |
Why?
| | Postoperative Complications | 2 | 2016 | 2167 | 0.150 |
Why?
| | Risk Factors | 11 | 2023 | 8714 | 0.150 |
Why?
| | Endoscopy | 1 | 1999 | 247 | 0.150 |
Why?
| | Practice Guidelines as Topic | 2 | 2022 | 1403 | 0.140 |
Why?
| | Clinical Trials as Topic | 1 | 2001 | 945 | 0.140 |
Why?
| | Sexual Maturation | 1 | 2017 | 47 | 0.140 |
Why?
| | Brain | 3 | 2017 | 2382 | 0.140 |
Why?
| | Immunization, Passive | 1 | 1997 | 79 | 0.140 |
Why?
| | Cytomegalovirus Retinitis | 1 | 2016 | 17 | 0.140 |
Why?
| | Adult | 17 | 2022 | 30817 | 0.140 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 184 | 0.140 |
Why?
| | Antibodies, Neutralizing | 2 | 2022 | 221 | 0.130 |
Why?
| | Nasal Mucosa | 2 | 2009 | 95 | 0.130 |
Why?
| | Hyperlipidemias | 1 | 2017 | 123 | 0.130 |
Why?
| | DNA, Viral | 2 | 2016 | 351 | 0.130 |
Why?
| | Adoption | 1 | 2016 | 39 | 0.130 |
Why?
| | Diagnosis, Differential | 2 | 2017 | 1358 | 0.130 |
Why?
| | Mice, Inbred ICR | 4 | 1997 | 111 | 0.130 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 1997 | 97 | 0.130 |
Why?
| | Child Development | 2 | 2017 | 394 | 0.130 |
Why?
| | Congenital Abnormalities | 2 | 2010 | 74 | 0.130 |
Why?
| | Sexually Transmitted Diseases | 1 | 2017 | 154 | 0.130 |
Why?
| | Lymphocyte Subsets | 1 | 2015 | 77 | 0.130 |
Why?
| | Ganciclovir | 1 | 2015 | 49 | 0.130 |
Why?
| | Chi-Square Distribution | 2 | 2013 | 502 | 0.120 |
Why?
| | Oropharynx | 1 | 2015 | 36 | 0.120 |
Why?
| | Lymphopenia | 1 | 2015 | 49 | 0.120 |
Why?
| | Incidence | 6 | 2017 | 2333 | 0.120 |
Why?
| | Muscle Hypotonia | 1 | 2015 | 31 | 0.120 |
Why?
| | Cranial Nerve Diseases | 1 | 2015 | 42 | 0.120 |
Why?
| | Cohort Studies | 6 | 2023 | 4961 | 0.120 |
Why?
| | Adenovirus Infections, Human | 2 | 1991 | 12 | 0.120 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2015 | 58 | 0.120 |
Why?
| | Rectum | 1 | 2015 | 151 | 0.120 |
Why?
| | Mycoses | 1 | 2014 | 67 | 0.120 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2013 | 27 | 0.110 |
Why?
| | Beclomethasone | 1 | 1993 | 25 | 0.110 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2015 | 147 | 0.110 |
Why?
| | Puberty, Delayed | 1 | 2013 | 5 | 0.110 |
Why?
| | Antibody Affinity | 1 | 2013 | 52 | 0.110 |
Why?
| | Giant Cells | 1 | 1993 | 21 | 0.110 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2013 | 37 | 0.110 |
Why?
| | Liver Transplantation | 1 | 2020 | 830 | 0.110 |
Why?
| | Candida | 1 | 2012 | 35 | 0.110 |
Why?
| | Cytomegalovirus Infections | 1 | 2015 | 180 | 0.110 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2017 | 965 | 0.110 |
Why?
| | Orthomyxoviridae | 1 | 2012 | 35 | 0.110 |
Why?
| | Viral Plaque Assay | 1 | 2012 | 22 | 0.110 |
Why?
| | Chickenpox | 1 | 1993 | 94 | 0.110 |
Why?
| | Hospital Design and Construction | 1 | 1992 | 3 | 0.100 |
Why?
| | Neutralization Tests | 1 | 2012 | 62 | 0.100 |
Why?
| | Bacterial Infections | 2 | 2009 | 222 | 0.100 |
Why?
| | Severity of Illness Index | 4 | 2021 | 2598 | 0.100 |
Why?
| | Aircraft | 1 | 1992 | 28 | 0.100 |
Why?
| | Drug Resistance, Viral | 1 | 2012 | 98 | 0.100 |
Why?
| | Gestational Age | 4 | 2015 | 757 | 0.100 |
Why?
| | HIV | 1 | 2013 | 209 | 0.100 |
Why?
| | Ureaplasma urealyticum | 1 | 1991 | 3 | 0.100 |
Why?
| | Chlamydia trachomatis | 1 | 1991 | 36 | 0.100 |
Why?
| | Prospective Studies | 7 | 2017 | 6267 | 0.100 |
Why?
| | Decision Support Techniques | 1 | 2015 | 352 | 0.100 |
Why?
| | Chorioamnionitis | 1 | 1991 | 36 | 0.100 |
Why?
| | Trophoblasts | 1 | 1993 | 162 | 0.100 |
Why?
| | Biomarkers | 1 | 2021 | 3474 | 0.090 |
Why?
| | Maternal-Fetal Exchange | 2 | 2007 | 151 | 0.090 |
Why?
| | Peritoneovenous Shunt | 1 | 1990 | 1 | 0.090 |
Why?
| | Meningitis, Aseptic | 1 | 1990 | 15 | 0.090 |
Why?
| | Poliovirus Vaccine, Oral | 1 | 1990 | 19 | 0.090 |
Why?
| | Rimantadine | 1 | 2010 | 2 | 0.090 |
Why?
| | Legionnaires' Disease | 1 | 1990 | 4 | 0.090 |
Why?
| | Adamantane | 1 | 2010 | 16 | 0.090 |
Why?
| | Cross Infection | 1 | 1992 | 202 | 0.090 |
Why?
| | Poliovirus | 1 | 1990 | 77 | 0.090 |
Why?
| | T-Lymphocytes | 2 | 2015 | 1754 | 0.090 |
Why?
| | Hepatitis B Antibodies | 1 | 2009 | 10 | 0.090 |
Why?
| | Mice | 8 | 2000 | 15073 | 0.090 |
Why?
| | Respiratory Tract Infections | 3 | 2016 | 323 | 0.080 |
Why?
| | Meningitis | 1 | 1990 | 74 | 0.080 |
Why?
| | Administration, Oral | 3 | 2012 | 731 | 0.080 |
Why?
| | Age Factors | 4 | 2017 | 2915 | 0.080 |
Why?
| | South Africa | 1 | 2009 | 162 | 0.080 |
Why?
| | Maxillary Sinus | 2 | 2009 | 11 | 0.080 |
Why?
| | Mucor | 2 | 2005 | 7 | 0.080 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 647 | 0.080 |
Why?
| | Body Fluids | 1 | 1987 | 58 | 0.070 |
Why?
| | Drug Administration Schedule | 2 | 2015 | 724 | 0.070 |
Why?
| | Evidence-Based Medicine | 3 | 2021 | 686 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2022 | 664 | 0.070 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2007 | 82 | 0.070 |
Why?
| | Aspergillosis | 2 | 2014 | 24 | 0.070 |
Why?
| | Virus Diseases | 1 | 2009 | 200 | 0.070 |
Why?
| | Organ Transplantation | 1 | 2009 | 161 | 0.070 |
Why?
| | Mitochondrial Diseases | 1 | 2007 | 77 | 0.070 |
Why?
| | Zygomycosis | 1 | 2006 | 6 | 0.070 |
Why?
| | Carotid Artery Thrombosis | 1 | 2005 | 7 | 0.070 |
Why?
| | Chronic Disease | 5 | 2009 | 1602 | 0.070 |
Why?
| | Logistic Models | 2 | 2023 | 1865 | 0.070 |
Why?
| | Animals | 9 | 2000 | 32122 | 0.060 |
Why?
| | Statistics as Topic | 1 | 2006 | 299 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2004 | 1216 | 0.060 |
Why?
| | Longitudinal Studies | 3 | 2018 | 2437 | 0.060 |
Why?
| | Drug Therapy, Combination | 2 | 2007 | 961 | 0.060 |
Why?
| | International Cooperation | 2 | 2018 | 175 | 0.060 |
Why?
| | Scedosporium | 1 | 2004 | 1 | 0.060 |
Why?
| | Herpesvirus 7, Human | 1 | 2004 | 5 | 0.060 |
Why?
| | Drug Resistance, Fungal | 1 | 2004 | 9 | 0.060 |
Why?
| | Roseolovirus Infections | 1 | 2004 | 6 | 0.060 |
Why?
| | Herpesvirus 6, Human | 1 | 2004 | 13 | 0.060 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2004 | 70 | 0.060 |
Why?
| | Respiratory Syncytial Viruses | 2 | 1997 | 47 | 0.060 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2004 | 139 | 0.060 |
Why?
| | Vaccines, Conjugate | 2 | 2014 | 60 | 0.050 |
Why?
| | Infant, Premature, Diseases | 2 | 1997 | 91 | 0.050 |
Why?
| | Biological Availability | 1 | 2003 | 119 | 0.050 |
Why?
| | Risk Assessment | 2 | 2020 | 3004 | 0.050 |
Why?
| | Disease Models, Animal | 3 | 2000 | 3583 | 0.050 |
Why?
| | Probability | 1 | 2003 | 297 | 0.050 |
Why?
| | Case-Control Studies | 3 | 2015 | 3056 | 0.050 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2007 | 448 | 0.050 |
Why?
| | Growth Disorders | 1 | 2022 | 78 | 0.050 |
Why?
| | Reference Values | 1 | 2003 | 745 | 0.050 |
Why?
| | Bacteria, Aerobic | 1 | 2001 | 7 | 0.050 |
Why?
| | Drug Combinations | 1 | 2022 | 288 | 0.050 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2001 | 80 | 0.050 |
Why?
| | Income | 1 | 2022 | 170 | 0.050 |
Why?
| | Adenosine Monophosphate | 1 | 2021 | 49 | 0.050 |
Why?
| | RNA | 2 | 2022 | 821 | 0.050 |
Why?
| | Drug Approval | 1 | 2021 | 78 | 0.050 |
Why?
| | Alanine | 1 | 2021 | 103 | 0.050 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2021 | 71 | 0.050 |
Why?
| | RNA Probes | 2 | 1991 | 13 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2021 | 173 | 0.050 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2000 | 30 | 0.040 |
Why?
| | Picornaviridae Infections | 2 | 1990 | 29 | 0.040 |
Why?
| | Necrosis | 1 | 2000 | 211 | 0.040 |
Why?
| | Remission Induction | 1 | 2020 | 240 | 0.040 |
Why?
| | Amniotic Fluid | 2 | 1991 | 64 | 0.040 |
Why?
| | Fungi | 2 | 2014 | 124 | 0.040 |
Why?
| | Otitis Media with Effusion | 1 | 1999 | 21 | 0.040 |
Why?
| | Cerebrospinal Fluid | 2 | 2004 | 88 | 0.040 |
Why?
| | Pharyngitis | 1 | 1999 | 23 | 0.040 |
Why?
| | Pseudallescheria | 1 | 1999 | 3 | 0.040 |
Why?
| | Time Factors | 1 | 2009 | 6186 | 0.040 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2005 | 3258 | 0.040 |
Why?
| | Zidovudine | 2 | 2010 | 77 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2003 | 1868 | 0.040 |
Why?
| | Opportunistic Infections | 1 | 1999 | 44 | 0.040 |
Why?
| | Spinal Cord | 1 | 2000 | 351 | 0.040 |
Why?
| | Chlamydiaceae Infections | 1 | 2017 | 1 | 0.040 |
Why?
| | Sex Factors | 2 | 2017 | 1743 | 0.040 |
Why?
| | Epidemiological Monitoring | 1 | 2018 | 47 | 0.040 |
Why?
| | Living Donors | 1 | 2020 | 324 | 0.040 |
Why?
| | Nutrition Disorders | 1 | 1997 | 23 | 0.040 |
Why?
| | B-Lymphocytes | 2 | 2015 | 770 | 0.040 |
Why?
| | Reoperation | 1 | 1999 | 526 | 0.040 |
Why?
| | Internationality | 1 | 2018 | 146 | 0.040 |
Why?
| | Abortion, Spontaneous | 1 | 1997 | 92 | 0.040 |
Why?
| | Tissue and Organ Procurement | 1 | 2020 | 243 | 0.040 |
Why?
| | Otitis Media | 1 | 1999 | 142 | 0.040 |
Why?
| | Ophthalmoscopy | 1 | 2016 | 30 | 0.040 |
Why?
| | Antigens, Viral | 1 | 2017 | 174 | 0.040 |
Why?
| | Heart | 1 | 2000 | 612 | 0.040 |
Why?
| | Acute Disease | 1 | 1999 | 917 | 0.030 |
Why?
| | Encephalomyelitis | 1 | 2016 | 9 | 0.030 |
Why?
| | Plasma Cells | 2 | 2009 | 57 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 1997 | 249 | 0.030 |
Why?
| | Immune Tolerance | 2 | 1999 | 331 | 0.030 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2015 | 34 | 0.030 |
Why?
| | AIDS Dementia Complex | 1 | 2015 | 50 | 0.030 |
Why?
| | North America | 1 | 2016 | 262 | 0.030 |
Why?
| | Caribbean Region | 1 | 2015 | 23 | 0.030 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2016 | 91 | 0.030 |
Why?
| | Malnutrition | 1 | 2016 | 63 | 0.030 |
Why?
| | Physical Conditioning, Animal | 1 | 1997 | 191 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2016 | 397 | 0.030 |
Why?
| | Audiometry | 1 | 2015 | 30 | 0.030 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2015 | 20 | 0.030 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2015 | 20 | 0.030 |
Why?
| | Latin America | 1 | 2015 | 69 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 123 | 0.030 |
Why?
| | Hematologic Neoplasms | 1 | 2016 | 135 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 1995 | 170 | 0.030 |
Why?
| | Biopsy | 3 | 2009 | 1056 | 0.030 |
Why?
| | Coinfection | 1 | 2016 | 120 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 970 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2017 | 364 | 0.030 |
Why?
| | Canada | 1 | 2015 | 337 | 0.030 |
Why?
| | Microscopy, Electron | 1 | 1995 | 406 | 0.030 |
Why?
| | Papillomavirus Vaccines | 1 | 2017 | 222 | 0.030 |
Why?
| | Combined Modality Therapy | 3 | 2005 | 1128 | 0.030 |
Why?
| | Neutropenia | 1 | 2015 | 127 | 0.030 |
Why?
| | Metabolic Diseases | 1 | 2015 | 99 | 0.030 |
Why?
| | Papillomavirus Infections | 1 | 2017 | 258 | 0.030 |
Why?
| | Evoked Potentials, Auditory, Brain Stem | 1 | 2015 | 52 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2015 | 374 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1444 | 0.030 |
Why?
| | Administration, Intranasal | 1 | 1993 | 76 | 0.030 |
Why?
| | Prognosis | 1 | 2001 | 3342 | 0.030 |
Why?
| | Mortality | 1 | 2015 | 293 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2017 | 442 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 733 | 0.030 |
Why?
| | Infant, Premature | 1 | 1997 | 477 | 0.030 |
Why?
| | Electromyography | 1 | 2015 | 325 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 1999 | 2409 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1333 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 382 | 0.030 |
Why?
| | Epidemiologic Studies | 1 | 2012 | 58 | 0.030 |
Why?
| | Oncology Service, Hospital | 1 | 1992 | 14 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2023 | 6438 | 0.030 |
Why?
| | Neisseria meningitidis | 1 | 2012 | 19 | 0.030 |
Why?
| | Meningococcal Infections | 1 | 2012 | 20 | 0.030 |
Why?
| | Ventilation | 1 | 1992 | 32 | 0.030 |
Why?
| | Ureaplasma Infections | 1 | 1991 | 3 | 0.030 |
Why?
| | Amniocentesis | 1 | 1991 | 21 | 0.030 |
Why?
| | Mycoplasma Infections | 1 | 1991 | 13 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2015 | 1058 | 0.030 |
Why?
| | Europe | 1 | 2012 | 352 | 0.030 |
Why?
| | Microbial Viability | 1 | 2012 | 79 | 0.020 |
Why?
| | Adenoviruses, Human | 1 | 1991 | 24 | 0.020 |
Why?
| | Comorbidity | 1 | 2016 | 1476 | 0.020 |
Why?
| | Hospitals, University | 1 | 1991 | 172 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2015 | 1056 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2013 | 225 | 0.020 |
Why?
| | Paramyxoviridae Infections | 1 | 1990 | 10 | 0.020 |
Why?
| | Respirovirus Infections | 1 | 1990 | 21 | 0.020 |
Why?
| | Chlamydia Infections | 1 | 1991 | 65 | 0.020 |
Why?
| | Rhinovirus | 1 | 1990 | 40 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 1995 | 1643 | 0.020 |
Why?
| | Population Surveillance | 1 | 1993 | 397 | 0.020 |
Why?
| | Benzoxazines | 1 | 2010 | 28 | 0.020 |
Why?
| | Inpatients | 1 | 2014 | 380 | 0.020 |
Why?
| | Cyclopropanes | 1 | 2010 | 81 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 1995 | 1728 | 0.020 |
Why?
| | Alkynes | 1 | 2010 | 54 | 0.020 |
Why?
| | Legionella | 1 | 1990 | 7 | 0.020 |
Why?
| | Cells, Cultured | 1 | 1997 | 3916 | 0.020 |
Why?
| | Leukemia | 1 | 1992 | 207 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 2 | 2015 | 3087 | 0.020 |
Why?
| | Dermatomyositis | 1 | 1989 | 23 | 0.020 |
Why?
| | Hospitals | 1 | 2014 | 582 | 0.020 |
Why?
| | Peroxidase | 1 | 2009 | 157 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2009 | 139 | 0.020 |
Why?
| | Respiratory Tract Diseases | 1 | 1990 | 142 | 0.020 |
Why?
| | Seasons | 1 | 1990 | 458 | 0.020 |
Why?
| | Natural Killer T-Cells | 1 | 2009 | 63 | 0.020 |
Why?
| | Muscles | 1 | 1989 | 328 | 0.020 |
Why?
| | Central Nervous System | 1 | 2010 | 239 | 0.020 |
Why?
| | Picornaviridae | 1 | 1988 | 18 | 0.020 |
Why?
| | Ribonucleases | 1 | 1987 | 53 | 0.020 |
Why?
| | HIV Reverse Transcriptase | 1 | 2007 | 29 | 0.020 |
Why?
| | Lamivudine | 1 | 2007 | 59 | 0.020 |
Why?
| | Antigens, CD | 1 | 2009 | 442 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 4449 | 0.020 |
Why?
| | Cavernous Sinus | 1 | 2005 | 14 | 0.020 |
Why?
| | Telencephalon | 1 | 2005 | 15 | 0.020 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2007 | 152 | 0.020 |
Why?
| | Orbit | 1 | 2005 | 59 | 0.020 |
Why?
| | Paranasal Sinuses | 1 | 2005 | 66 | 0.020 |
Why?
| | Exocrine Glands | 1 | 2004 | 4 | 0.010 |
Why?
| | Basement Membrane | 1 | 2004 | 29 | 0.010 |
Why?
| | Prevalence | 1 | 2010 | 2271 | 0.010 |
Why?
| | Neutrophils | 1 | 2009 | 1170 | 0.010 |
Why?
| | Cell Count | 1 | 2004 | 304 | 0.010 |
Why?
| | Lymphocytes | 1 | 2004 | 342 | 0.010 |
Why?
| | Macrophages | 1 | 2009 | 1281 | 0.010 |
Why?
| | Eosinophils | 1 | 2004 | 283 | 0.010 |
Why?
| | Penicillin Resistance | 1 | 2001 | 8 | 0.010 |
Why?
| | Haemophilus influenzae | 1 | 2001 | 50 | 0.010 |
Why?
| | beta-Lactamases | 1 | 2001 | 26 | 0.010 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2001 | 62 | 0.010 |
Why?
| | Staphylococcus | 1 | 2001 | 69 | 0.010 |
Why?
| | Drug Resistance, Bacterial | 1 | 2001 | 156 | 0.010 |
Why?
| | Nasal Decongestants | 1 | 1999 | 8 | 0.010 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 1999 | 33 | 0.010 |
Why?
| | Steroids | 1 | 1999 | 147 | 0.010 |
Why?
| | Recurrence | 1 | 1999 | 949 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 1999 | 447 | 0.010 |
Why?
| | Patient Selection | 1 | 1999 | 656 | 0.010 |
Why?
| | RNA, Antisense | 1 | 1988 | 16 | 0.010 |
Why?
| | DNA, Recombinant | 1 | 1988 | 42 | 0.000 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1988 | 150 | 0.000 |
Why?
| | Aged | 1 | 2006 | 19299 | 0.000 |
Why?
| | Virus Replication | 1 | 1988 | 392 | 0.000 |
Why?
| | Middle Aged | 1 | 2006 | 27083 | 0.000 |
Why?
| | Cell Line | 1 | 1988 | 2655 | 0.000 |
Why?
| | DNA | 1 | 1988 | 1358 | 0.000 |
Why?
|
|
Abzug's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|